中文名 | ML228 |
英文名 | ML228 |
英文别名 | ML228 L-228 KC7F2 ML-228 ML 228 CID-46742353 N-([1,1'Biphenyl]-4-ylmethyl)-6-phenyl-3-(2-pyridinyl)-1,2,4-triazin-5-amine N-([1,1-Biphenyl]-4-ylmethyl)-6-phenyl-3-(pyridin-2-yl)-1,2,4-triazin-5-amine 1,2,4-Triazin-5-amine, N-([1,1'-biphenyl]-4-ylmethyl)-6-phenyl-3-(2-pyridinyl)- |
CAS | 1357171-62-0 |
化学式 | C27H21N5 |
分子量 | 415.49 |
密度 | 1.228±0.06 g/cm3(Predicted) |
沸点 | 686.0±65.0 °C(Predicted) |
溶解度 | DMSO (微溶) 、甲醇 (微溶) |
酸度系数 | 2.03±0.63(Predicted) |
存储条件 | -20°C, Inert atmosphere |
外观 | 固体 |
颜色 | Pale Yellow to Light Yellow |
体外研究 | ML228 (CID-46742353) represents a novel chemotype available to the research community for the study of HIF activation and its therapeutic potential. Not only is the compound substantially different in structure from known HIF activators, ML228 lacks the acidic functional group almost universally present in PHD inhibitors, which may be important for certain disease applications. |
体内研究 | ML228 (injection; 1 µg/kg; 7 days) treatments following spinal cord injury (SCI) improves the local hypoxic ischemia environment, reduce SCI secondary injury and promote the recovery of neurological function. Animal Model: SD rat Dosage: 1 µg/kg Administration: injection; 7 days Result: Alleviated SCI of the central nervous system and relieve associated symptoms. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.407 ml | 12.034 ml | 24.068 ml |
5 mM | 0.481 ml | 2.407 ml | 4.814 ml |
10 mM | 0.241 ml | 1.203 ml | 2.407 ml |
5 mM | 0.048 ml | 0.241 ml | 0.481 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!